A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
2.
METHOD FOR PRODUCING SUGAR INCLUDING LACTO-N-TRIOSE II AS CORE TRISACCHARIDE AND METHOD FOR PRODUCING CRYSTALS OF SAID SUGAR
The present invention relates to a microorganism having a reduced or inactivated activity of a protein according to any one of the following [1] to [3] and improved productivity of lacto-N-triose II or an oligosaccharide having a lacto-N-triose II (LNTII) skeleton as compared with a parent strain: [1] a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein having an oligosaccharide transporting activity and consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 2 or 4, and [3] a homologous protein having an oligosaccharide transporting activity and consisting of an amino acid sequence having an identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2 or 4.
Provided are a recombinant microorganism having an ability to produce heterologous CTP:phosphocholine cytidylyltransferase, in which the CTP:phosphocholine cytidylyltransferase is a polypeptide having a CTP:phosphocholine cytidylyltransferase activity and consisting of a specific amino acid sequence, and a method for producing CDP-choline using the recombinant microorganism.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12P 19/40 - Nucléosides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléosides puriques
4.
COMPOSITION FOR PREVENTING OR ALLEVIATING HEPATIC DYSFUNCTION
Disclosed is a composition for preventing or alleviating hepatic dysfunction, the composition containing a trisulfide compound represented by formula (1) or (6), a pharmaceutically acceptable salt thereof, or a cyclodextrin inclusion of the same.
A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
5.
METHOD FOR PRODUCING 4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID
C12P 13/00 - Préparation de composés organiques contenant de l'azote
6.
MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM
An object of the present invention is to provide a microorganism having an ability to produce NeuAc and/or a NeuAc-containing carbohydrate, and a method for producing NeuAc and/or the NeuAc-containing carbohydrate more efficiently by the microorganism. The present invention relates to a microorganism which has an ability to produce NeuAc and/or a NeuAc-containing carbohydrate and whose enterobacterial common antigen (ECA) biosynthesis pathway is blocked, and a method for producing NeuAc and/or the NeuAc-containing carbohydrate using the microorganism.
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Tatsumi, Ryuichi
Nakamura, Mako
Ohshima, Etsuo
Abrégé
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents —OR1 or —NR2R3, R1 represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2 and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof.
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents —OR1 or —NR2R3, R1 represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2 and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
8.
MODIFIED PROTEIN HAVING ALPHA1,2-FUCOSYLTRANSFERASE ACTIVITY AND METHOD FOR PRODUCING FUCOSE-CONTAINING CARBOHYDRATE
An object of the present invention is to provide a modified protein having an α1,2-fucosyltransferase activity and a method for producing a fucose-containing carbohydrate using the protein or a microorganism having an ability to produce the protein. According to the present invention, a fucose-containing carbohydrate such as 2′-fucosyllactose can be more efficiently produced by using a protein having an α1,2-fucosyltransferase activity and being modified to substitute a specific amino acid residue with another amino acid residue, or a microorganism having the protein or an ability to produce the protein, compared to the case of using a wild-type protein having an α1,2-fucosyltransferase activity, or a microorganism having the protein or an ability to produce the protein.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
9.
PROTEIN HAVING 1,3-FUCOSYLTRANSFERASE ACTIVITY, AND METHOD FOR PRODUCING FUCOSE-CONTAINING SUGAR
An object of the present invention is to provide a method for producing a fucose-containing carbohydrate more efficiently as compared with that in related art. The present invention relates to any one protein of [1] a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein having an α1,3-fucosyltransferase activity and consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 2 or 4, and [3] a homologous protein having an α1,3-fucosyltransferase activity and consisting of an amino acid sequence having an identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2 or 4.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ohshima Etsuo
Tatsumi Ryuichi
Nakamura Mako
Abrégé
Disclosed is an enhancer of the physiological activity of a hepatocyte growth factor, the enhancer comprising a trisulfide compound. The trisulfide compound comprises at least one component selected from the group consisting of glutathione trisulfide, a pharmaceutically acceptable salt of glutathione trisulfide, a compound represented by formula (1), a pharmaceutically acceptable salt of the compound, a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt, a compound represented by formula (6), a pharmaceutically acceptable salt of the compound, and a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt.
An object of the invention is to provide a method for producing a lactose-containing oligosaccharide through more efficient fermentative production. According to the invention, using a microorganism having an ability of producing a protein which is modified by replacing a specific amino acid residue with a different amino acid residue and which has lactose permease activity, a lactose-containing oligosaccharide such as 2′-fucosyllactose can be produced more efficiently as compared to the case using a microorganism having an ability of producing the wild-type protein having lactose permease activity.
A prophylactic or therapeutic agent for acute renal failure that includes glutathione trisulfide or a pharmacolgically acceptable salt thereof; and a method for determining at least one among the advisability, the method of administration, and the dosage of glutathione trisulfide or a pharmacolgically acceptable salt thereof on the basis of GDF-15 concentration in the blood.
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
13.
AGENT FOR IMPROVING ENDURANCE AND/OR REDUCING PHYSICAL FATIGUE
The present invention relates to: an agent for improving endurance and/or reducing physical fatigue that contains sialyllactose or a salt thereof as an active ingredient; use of sialyllactose or a salt thereof to produce the agent; sialyllactose or a salt thereof to be used as the agent; a method for improving endurance and/or reducing physical fatigue; a composition that is at least one of an adenosine monophosphate protein kinase activator and compositions for preventing sarcopenia, for improving lipid metabolism, for improving insulin resistance, and for improving glucose metabolism; a glycogen synthase activator; and a composition for improving endurance.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
Disclosed is a prophylactic or therapeutic agent that is for acute kidney injury induced by an anticancer agent and that contains at least one selected from the group consisting of: glutathione trisulfide and pharmacologically acceptable salts thereof; at least one cyclodextrin inclusion complex selected from the group consisting of lipoic acid trisulfide, derivatives of the same, and pharmacologically acceptable salts thereof; lipoic acid trisulfide and derivatives thereof; and pantethine trisulfide and pharmacologically acceptable salts thereof. The present invention also discloses a method for determining, on the basis of a blood GDF-15 level, at least one of the dosage, the dosage regimen, and the administration feasibility of the prophylactic or therapeutic agent.
The present invention relates to a composition which contains an intestinal bacterium belonging to the genus Veillonella and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to a composition which contains an intestinal bacterium belonging to Bacteroidetes and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
An object of the present invention is to provide a protein having dipeptide synthesizing activity with improved substrate specificity, and a method in which the protein or a microorganism having ability to produce the protein is used to efficiently produce a target dipeptide while reducing a by-product dipeptide produced in addition to the target dipeptide. According to the present invention, a protein consisting of an amino acid sequence obtained by substituting, with other amino acid residues, amino acid residues corresponding to one or more amino acid residues selected from the group consisting of amino acid residues at positions 107, 108, and 110 in an amino acid sequence set forth in SEQ ID NO: 2, or a mutant protein or a homologous protein of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is provided, and a microorganism producing the protein can be used to efficiently produce a dipeptide.
An object of the present invention is to provide a method for efficiently producing a fucose-containing carbohydrate by using a protein associated with transport of a fucose-containing carbohydrate and a microorganism having an ability to produce the protein. The present invention relates to any one protein of [1] a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein having a transporting activity for a fucose-containing carbohydrate and consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 2 or 4, and [3] a homologous protein having a transporting activity for a fucose-containing carbohydrate and consisting of an amino acid sequence having an identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2 or 4.
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for use in the manufacture of foods and drinks;
chemicals for use in the manufacture of supplements;
chemicals for use in the manufacture of pharmaceuticals;
additives to foods [chemicals]; chemicals; higher fatty
acids; artificial sweeteners; flour and starch for
industrial purposes; milk ferments for chemical purposes;
bacteria for use in the manufacture of food; cultures of
microorganisms, other than for medical and veterinary use.
21.
METHOD FOR PRODUCING 4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID
A production method of one embodiment, said production method being for producing a 4-(aminomethyl)cyclohexane-1-carboxylic acid from 1,4-bis(aminomethyl)cyclohexane, comprises using a protein that comprises an amino acid sequence having 60% or more identity with an amino acid sequence represented by one of SEQ ID NOS: 1-4 and 103-105 and has aminotransferase activity, and a protein that comprises an amino acid sequences having 50% or more identity with an amino acid sequence represented by one of SEQ ID NOS: 19-22, 35-46 and 127-139 and has aldehyde dehydrogenase activity.
The present invention relates to a microorganism which has an enhanced activity of a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by deletion of 20-37 amino acid residues on the N-terminal side, and which has an improved productivity of 3'-sialyllactose compared to the parent strain.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
A health improvement path search device including: a first model generating unit configured to generate a first model predicting a value of a health index; a second model generating unit configured to generate a second model deriving a presence probability; and a path searching unit configured to derive the value of the health index and the presence probability corresponding to each measurement target value specify a plurality of paths transitioning to each of the measurement target values from the current values as start points, specify paths in which the value of the health index at an end point is improved from the current value of the health index among the plurality of paths as candidate paths, and specify a path for which a product of the presence probabilities of the measurement target values included in the candidate path is a maximum as a health improvement path.
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
24.
PROTEIN HAVING NAMPT ACTIVITY, AND METHOD FOR PRODUCING NMN
A protein according to the present invention is a protein which is disclosed in any one among [1]-[3], and which has nicotinamide phosphoribosyltransferase activity. [1] A protein comprising an amino acid sequence represented by SEQ ID NO: 3 or 5. [2] A mutated protein comprising an amino acid sequence represented by SEQ ID NO: 3 or 5, wherein 1-20 amino acids are missing, substituted, inserted, or added to the amino acid sequence. [3] A homologous protein comprising an amino acid sequence with at least 90% identity to an amino acid sequence represented by SEQ ID NO: 3 or 5.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
L-Alanyl-L-Glutamine, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, cosmetics, foods and dietary supplements; Amino acid peptides, other than for medical or veterinary purposes, for use in the manufacture of pharmaceuticals, cosmetics, foods and dietary supplements; Chemical additives for use in the manufacture of pharmaceuticals, cosmetics, foods and dietary supplements; L-Alanyl-L-Glutamine, namely, active chemical ingredients for use in the manufacture of culture medium supplements or culture medium additives other than for medical or veterinary use; Chemicals for use in the manufacture of pharmaceuticals, cosmetics, foods and dietary supplements L-Alanyl-L-Glutamine, namely chemical preparations for culture medium supplements or culture medium additives for medical or veterinary use for supporting overall health, well-being, and athletic performance; Dietary supplements
An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/20 - Antiviraux pour le traitement des virus ADN
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Miyamoto Aya
Ogino Fumiko
Koizumi Keiichi
Mori Hisashi
Abrégé
The purpose of the present invention is to provide a glutaminase inhibitor effective for prophylaxis, amelioration or therapy of cancer, inflammatory disease, nervous system disease, aging and obesity. The present invention pertains to a glutaminase inhibitor comprising, as an active component, at least one substance selected from the group consisting of peptides, L-carnitine, N2-(1-oxopropyl)-L-glutamine, N2-(1-oxobutyl)-L-glutamine, sialic acid, eucomic acid and (4)-imidazoleacetic acid hydrochloride or a pharmaceutically acceptable salt thereof.
An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
30.
METHOD FOR PRODUCING SUGAR INCLUDING LACTO-N-TRIOSE II AS CORE TRISACCHARIDE AND METHOD FOR PRODUCING CRYSTALS OF SAID SUGAR
The present invention relates to microorganisms that have enhanced, reduced, or inactivated activity of any of [1] a protein composed of an amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein that is composed of an amino acid sequence in which 1-20 amino acids in the amino acid sequence represented by SEQ ID NO: 2 or 4 have been deleted, substituted, inserted, or added and that has oligosaccharide transport activity, and [3] a homologous protein that is composed of an amino acid sequence having 90% or greater identity with the amino acid sequence represented by SEQ ID NO: 2 or 4 and that has oligosaccharide transport activity, the microorganisms also having improved productivity of lacto-N-triose II or an oligosaccharide having a lacto-N-triose II skeleton over that of a parent strain.
The invention provides a method for improving attention of a healthy human subject by administering an effective amount of citidine-5′-diphosphocholine or a salt thereof to a healthy human subject.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/6615 - Composés ayant plusieurs groupes d'acide du phosphore estérifiés, p. ex. triphosphate d'inositol, acide phytique
32.
MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM
A purpose of the present invention is to provide a microorganism having the ability to produce NeuAc and/or an NeuAc-containing carbohydrate and a method for producing NeuAc and/or an NeuAc-containing carbohydrate efficiently by said microorganism. The present invention relates to a microorganism having the ability to produce NeuAc and/or an NeuAc-containing carbohydrate and having a blocked enterobacterial common antigen (ECA) biosynthesis pathway and to a method for producing NeuAc and/or an NeuAc-containing carbohydrate using said microorganism.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Tatsumi Ryuichi
Nakamura Mako
Ohshima Etsuo
Abrégé
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents -OR1or -NR2R3, R1represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof.
A recombinant microorganism having a capability of producing xenogeneic CTP:phosphocholine cytidylyltransferase, wherein the CTP:phosphocholine cytidylyltransferase is a polypeptide formed of a specific amino acid sequence and having a CTP:phosphocholine cytidylyltransferase activity. A method for producing CDP-choline, the method comprising producing CDP-choline by using said recombinant microorganism.
C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
35.
RECOMBINANT MICROORGANISM USED FOR PRODUCING CDP-CHOLINE, AND METHOD FOR PRODUCING CDP-CHOLINE USING SAID RECOMBINANT MICROORGANISM
Provided are a recombinant microorganism having an ability to produce heterologous CTP:phosphocholine cytidylyltransferase, in which the CTP:phosphocholine cytidylyltransferase is a polypeptide having a CTP:phosphocholine cytidylyltransferase activity and consisting of a specific amino acid sequence, and a method for producing CDP-choline using the recombinant microorganism.
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
36.
METHOD FOR PRODUCING CYTIDINE 5'-DIPHOSPHATE COMPOUND
The purpose of the present invention is to provide a method for producing a cytidine 5'-diphosphate compound, in which cytidine 5'-phosphate can be efficiently separated from a crude cytidine 5'-diphosphate compound to concentrate the cytidine 5'-diphosphate compound to a higher concentration than that before the purification. This method for producing a cytidine 5'-diphosphate compound includes (1) a step in which a solution containing the cytidine 5'-diphosphate compound is brought into contact with a basic ion-exchange resin to adsorb the cytidine 5'-diphosphate compound onto the basic ion-exchange resin and (2) a step in which an aqueous solution containing an organic acid having two or more carbon atoms is used to elute the cytidine 5'-diphosphate compound adsorbed onto the basic ion-exchange resin, thereby obtaining an eluate, the cytidine 5'-diphosphate compound being one having a cationic substituent.
The present invention relates to a method for producing a cytidine-5'-diphosphate compound. The method includes: (1) a step of bringing a solution containing a cytidine-5'-diphosphate compound into contact with a basic ion exchange resin to adsorb the cytidine-5'-diphosphate compound onto the basic ion exchange resin, and (2) a step of obtaining an eluate by eluting the cytidine-5'-diphosphate compound adsorbed onto the basic ion exchange resin using an aqueous solution containing an organic acid having 2 or more carbon atoms. The cytidine-5'-diphosphate compound is a cytidine-5'-diphosphate compound having a cationic substituent.
The present invention relates to a method for producing a cytidine-5'-diphosphate compound, the method comprising: (1) a step in which a solution containing a cytidine-5'-diphosphate compound is brought into contact with a basic ion exchange resin, thereby having the cytidine-5'-diphosphate compound adsorbed on the basic ion exchange resin; and (2) a step in which an eluate is obtained by eluting the cytidine-5'-diphosphate compound adsorbed on the basic ion exchange resin with use of an aqueous solution that contains an organic acid having 2 or more carbon atoms. With respect to this method for producing a cytidine-5'-diphosphate compound, the cytidine-5'-diphosphate compound has a cationic substituent.
A prophylactic or therapeutic agent for acute renal failure that includes glutathione trisulfide or a pharmacolgically acceptable salt thereof; and a method for determining at least one among the advisability, the method of administration, and the dosage of glutathione trisulfide or a pharmacolgically acceptable salt thereof on the basis of GDF-15 concentration in the blood.
The present invention pertains to: a composition that comprises an intestinal bacterium belonging to the phylum Bacteroides and having an inflammation reducing effect or a substance derived from the intestinal bacterium and having an inflammation reducing effect, and that has at least one effect selected from among anti-inflammatory, immunomodulatory, epithelial barrier repair, IL-10 induction and IL-22 induction effects; and an ameliorating agent for inflammatory, autoimmune or infectious diseases that comprises the aforesaid intestinal bacterium or a substance derived from the intestinal bacterium and having an inflammation reducing effect.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Yasuo Shinobu
Hishida Yukihiro
Abrégé
The present invention pertains to: a ghrelin receptor sensitivity-enhancing agent that contains ornithine or a salt thereof as an active ingredient; a composition that contains ornithine or a salt thereof as an active ingredient and that is used for at least one selected from improved memory, dementia amelioration, neurogenesis, neuroprotection against neurodegeneration, cardiovascular function control, osteoblast proliferation promotion, osteogenesis promotion, heart failure prevention, and chronic obstructive pulmonary disease (COPD) amelioration; and a ghrelin receptor activation method that includes the administration of an effective dose of ornithine or a salt thereof.
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
The present invention relates to a composition that includes an intestinal bacterium belonging to the genus Veillonella having an inflammation-suppressing action or a substance having an inflammation-suppressing action derived from said intestinal bacterium and has at least one action selected from an anti-inflammatory action, an immunomodulatory action, an epithelial barrier repair action, an IL-10 inducing action, and an IL-22 inducing action and to an improving agent for an inflammatory disease, an autoimmune disease, or an infection that includes said intestinal bacterium or a substance having an inflammation-suppressing action derived from said intestinal bacterium.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The purpose of the present invention is to provide a method for producing a fucose-containing carbohydrate by using a modified protein having an α1,2-fucosyltransferase activity and a microorganism having the protein or capable of producing the protein. According to the present invention, a fucose-containing carbohydrate such as 2'-fucosyl lactose can be produced more efficiently by using a protein, said protein being modified to substitute a specific amino acid residue with another amino acid residue and having an α1,2-fucosyltransferase activity, and a microorganism having the protein or capable of producing the protein, compared to the case of using a wild-type protein having an α1,2-fucosyltransferase activity and a microorganism having the protein or capable of producing the protein.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
44.
PROTEIN HAVING 1,3-FUCOSYLTRANSFERASE ACTIVITY, AND METHOD FOR PRODUCING FUCOSE-CONTAINING SUGAR
The purpose of the present invention is to provide a means for producing a fucose-containing sugar more efficiently compared with the conventional techniques. The present invention relates to any one protein selected from: [1] a protein which comprises the amino acid sequence represented by SEQ ID NO: 2 or 4; [2] a mutant protein which comprises an amino acid sequence having a structure such that 1 to 20 amino acid residues are deleted, substituted, inserted or added in the amino acid sequence represented by SEQ ID NO: 2 or 4 and has an α1,3-fucosyltransferase activity; and [3] a homologous protein which comprises an amino acid sequence having a 90% or higher identity to the amino acid sequence represented by SEQ ID NO: 2 or 4 and has an α1,3-fucosyltransferase activity.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
45.
PROTEIN HAVING FUCOSE-CONTAINING SUGAR TRANSPORTING ACTIVITY, AND METHOD FOR PRODUCING FUCOSE-CONTAINING SUGAR
The purpose of the present invention is to provide: a protein involved in the transport of a fucose-containing sugar; and a method for producing a fucose-containing sugar efficiently using a microorganism capable of producing the protein. The present invention relates to any one protein selected from [1] a protein which comprises the amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein which comprises an amino acid sequence having a structure such that 1 to 20 amino acid residues are deleted, substituted, inserted or added in the amino acid sequence represented by SEQ ID NO: 2 or 4 and has a fucose-containing sugar transporting activity, and [3] a homologous protein which comprises an amino acid sequence having a 90% or higher identity to the amino acid sequence represented by SEQ ID NO: 2 or 4 and has a fucose-containing sugar transporting activity.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A supplement supply support device includes an acquisition unit configured to acquire information pertaining to training of a user, and a supplement determination unit configured to determine supply conditions of a supplement according to the information pertaining to training of a user on the basis of a recommendation algorithm for recommending supply conditions of a supplement in accordance with information pertaining to training.
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p. ex. les régimes
47.
HEALTH IMPROVEMENT PATH SEARCH DEVICE AND HEALTH IMPROVEMENT PATH SEARCH METHOD
A health improvement path search device according to the present invention comprising: a first model generating unit for generating a first model for predicting, on the basis of the values of a plurality of explanatory variables, a value of a health index that is an objective variable; a second model generating unit for generating a second model for deriving an existence probability for each combination of the values of the plurality of explanatory variables input into the first model and the predicted health index value; and a path search unit which, using a plurality of measurement target values as inputs and on the basis of the first model and the second model, derives a health index value and an existence probability corresponding to each measurement target value, identifies a plurality of paths that transition between the measurement target values starting from a current value, identifies, as candidate paths among the plurality of paths, paths in which the health index value at an end point is improved over the health index value at the current value, and identifies as a health improving path a path included in the candidate paths in which the product of the existence probabilities of the measurement target values is at a maximum.
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
The present invention addresses the problem of providing: a protein having improved substrate specificity and having dipeptide synthetic activity; and a method for producing a desired dipeptide, the method using said protein or a microorganism capable of producing said protein to reduce by-product dipeptides other than the desired dipeptide and to efficiently produce the desired dipeptide. The present invention provides a protein comprising an amino-acid sequence represented by SEQ ID NO: 2 or an amino acid sequence of a mutant or a homolog of the protein comprising the amino acid sequence represented by SEQ ID NO: 2, wherein amino acid residues corresponding to one or more amino acid residues at positions selected from the group consisting of position 107, position 108, and position 110 are substituted with other amino acid residues. Furthermore, the present invention is capable of efficiently producing dipeptides by utilizing a microorganism that produces said protein.
An object of the present invention is to provide a microorganism that efficiently produces a PUFA and a method for producing a PUFA using the microorganism. The present invention relates to a microorganism capable of producing a polyunsaturated fatty acid (PUFA), in which a gene encoding an exogenous polyketide synthase dehydratase (PS-DH) domain having a higher activity against 3-hydroxyhexanoyl acyl carrier protein (3-hydroxyhexanoyl ACP) than an endogenous FabA-like β-hydroxyacyl-ACP dehydratase (FabA-DH) domain has been introduced into a microorganism having a PUFA metabolic pathway, and the like.
An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
C07C 277/06 - Purification ou séparation de guanidine
C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
52.
Non-solvate crystal of eucomic acid and method for producing same
An object of the present invention is to provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity, and a method for producing the same. The present invention can provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity by drying a methanol solvate crystal of eucomic acid.
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
C07C 59/52 - Composés non saturés contenant des groupes hydroxyle ou O-métal un groupe hydroxyle ou O-métal étant lié à un atome de carbone d'un cycle aromatique à six chaînons
53.
MICROORGANISM HAVING MODIFIED LACTOSE PERMEASE, AND METHOD FOR PRODUCING LACTOSE-CONTAINING OLIGOSACCHARIDE
The purpose of the present invention is to provide a more efficient method for producing a lactose-containing oligosaccharide by fermentation production. According to the present invention, a microorganism capable of producing a protein having the activity of a lactose permease that is modified in such a manner that a specific amino acid residue is substituted by another amino acid residue is used, whereby it becomes possible to produce a lactose-containing oligosaccharide, e.g., 2'-fucosyllactose, more efficiently compared with a case where a microorganism capable of producing a protein having the activity of the lactose permease of the wild type is used.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
54.
METHOD AND REAGENT FOR DETECTING BACTERIUM INVOLVED WITH DEVELOPMENT OF RHEUMATOID ARTHRITIS, AND METHOD AND AGENT FOR DETERMINING PRESENCE OR ABSENCE OF PREDISPOSITION TO RHEUMATOID ARTHRITIS
The objective of the present invention is to provide a means for identifying a bacterium associated with the development of rheumatoid arthritis and determining the possibility of contracting rheumatoid arthritis earlier and more easily using the bacterium. The present invention relates to a method and reagent for detecting a bacterium involved with the development of rheumatoid arthritis, and a method and agent for determining the presence or absence of a predisposition to rheumatoid arthritis.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
55.
Agent for preventing or improving decline in brain function
An object of the invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients is provided.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
56.
METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCE, RECOMBINANT CELLS AND METHOD FOR PRODUCING SAME
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Kamihira Masamichi
Kawabe Yoshinori
Sagawa Kosuke
Toida Toshihiko
Koizumi Satoshi
Abrégé
The purpose of the present invention is to provide a production method whereby a heparin-like substance is efficiently produced without using an animal-derived tissue. The present invention pertains to a method for producing a heparin-like substance, etc., said method comprising: (1) a step for preparing mammalian cells producing the heparin-like substance; (2) a step for preparing recombinant cells wherein a gene encoding the extracellular domain of syndecan is introduced into the heparin-like substance-producing mammalian cells prepared in step (1); and (3) a step for culturing the recombinant cells prepared in step (2) in a medium and collecting the heparin-like substance from the culture supernatant thus obtained.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
KYOWA HAKKO BIO CO., LTD. (Japon)
Inventeur(s)
Sawa Tomohiro
Matsuno Shinya
Abrégé
A compound represented by R1nnSR2(R1and R2 each independently represent a residue obtained by removing one thiol group from a thiol-group-containing compound, and n represents an integer equal to or greater than 1) or a pharmacologically acceptable salt thereof raises the in vivo concentration of active sulfur molecular species.
A61K 8/46 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du soufre
The invention provides a tablet that contains free-form arginine at a high content, suppresses cracking and collapse due to moisture absorption, is superior in preservation stability and permits convenient production. The tablet contains free-form arginine at a concentration of not less than 5 mass % of the total amount of the tablet and can be obtained by compression molding free-form arginine dried by a spray dry method.
A supplement supply support device comprising: an acquisition unit that obtains information pertaining to user training; and a supplement determination unit that, on the basis of a recommendation algorithm that recommends a supply mode for a supplement in accordance with training information, determines a supply mode for a supplement in accordance with the training information for the user.
A63B 69/00 - Appareils d'entraînement ou appareils destinés à des sports particuliers
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
The present invention addresses the problem of providing: a composition that contains a polysulfide compound having improved stability or a pharmaceutically acceptable salt thereof; an agent for improving the stability of the polysulfide compound or of a pharmaceutically acceptable salt thereof; and a method for improving the stability of the polysulfide compound or of a pharmaceutically acceptable salt thereof. The present invention makes it possible to provide a composition that contains a polysulfide compound having improved stability or a pharmaceutically acceptable salt thereof by causing a polysulfide compound or a pharmaceutically acceptable salt thereof to coexist with one or more compounds selected from the group consisting of stabilizing agents and unsaturated hydrocarbon compounds.
A61J 1/00 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
According to the present invention, theanine can efficiently be produced without exogenously adding ethylamine and without accumulation or leftover of ethylamine as a byproduct, by using a microorganism having enhanced activity to produce ethylamine with acetaldehyde and alanine as substrates and having enhanced activity of γ-glutamylmethylamide synthetase or glutaminase.
The invention provides citrulline or a salt thereof and glutathione or a salt thereof for use in increasing a ratio of muscle mass to total body weight in a person in conjunction with a resistance workout program, as well as a method of increasing a ratio of muscle mass to total body weight in a person by administering citrulline or a salt thereof and glutathione or a salt thereof to the person in conjunction with a resistance workout program. The citrulline and glutathione or salts thereof are administered daily for a period greater than 7 days, whereas the resistance workout program is administered for at least the entire period during which the two compounds are administered. The muscle mass is measured by a body composition meter.
C07K 5/093 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p. ex. Asp, Glu, Asn
64.
Crystal of glutathione trisulfide dihydrate and method for producing same
The present invention relates to a crystal of glutathione trisulfide dihydrate and a method for producing the same. According to the present invention, for example, the crystal can be provided by concentrating an aqueous solution in which glutathione trisulfide is dissolved and collecting the precipitated crystal of glutathione trisulfide dihydrate. In addition, the present invention relates to a simple method for producing polysulfide in an aqueous solvent using thiosulfate without using hydrogen sulfide, by stirring an aqueous solution in which a compound having a thiol group or a disulfide bond and thiosulfate are dissolved or by leaving the aqueous solution to stand.
C07K 5/093 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p. ex. Asp, Glu, Asn
65.
MICROORGANISM PRODUCING EICOSAPENTAENOIC ACID AND METHOD FOR PRODUCING EICOSAPENTAENOIC ACID
The purpose of the present invention is to provide a microorganism that efficiently produces an EPA and a method for producing an EPA using said microorganism. The present invention relates to a microorganism having the ability to produce a docosahexaenoic acid (DHA), wherein the microorganism or the like contains a protein (variant OrfB) comprising an amino acid sequence in which at least one of the sixth, 65th, 230th, 231st, and 275th amino acid residues in the amino acid sequence represented by SEQ ID NO: 2 is substituted with another amino acid residue, and is capable of producing an eicosapentaenoic acid (EPA).
C12N 1/11 - ProtozoairesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/13 - Algues unicellulairesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
C12N 15/30 - Gènes codant pour des protéines protozoaires, p. ex. Plasmodium, Trypanosoma, Eiméria
The purpose of the present invention is to provide a microorganism that efficiently produces a PUFA and a method for producing a PUFA using said microorganism. The present invention relates to a microorganism or the like capable of producing a PUFA, wherein a gene coding for an exogenous polyketide synthase dehydratase (PS-DH) domain, which has higher activity for a 3-hydroxyhexanoyl acyl carrier protein (3-hydroxyhexanoyl ACP) than an endogenous FabA-like β-hydroxyacyl-ACP dehydratase (FabA-DH) domain has, is introduced into a microorganism having a polyunsaturated-fatty-acid (PUFA) metabolic pathway.
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
The purpose of the present invention is to provide: crystals of a eucomic acid non-solvate which have a low methanol content and excellent flowability; and a method for producing the crystals. The crystals of a eucomic acid non-solvate, which have a low methanol content and excellent flowability, can be provided by drying crystals of eucomic acid solvated with methanol.
C07C 59/52 - Composés non saturés contenant des groupes hydroxyle ou O-métal un groupe hydroxyle ou O-métal étant lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
68.
Crystal of L-alanyl-L-glutamine and method for producing same
An object of the present invention is to provide a crystal of L-alanyl-L-glutamine having a low loose specific volume, and a method for producing the same. The present invention relates to a crystal of L-alanyl-L-glutamine in which the loose specific volume is 5.0 mL/g or less, and a method for producing the same.
C07C 237/04 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
G01N 23/207 - Diffractométrie, p. ex. en utilisant une sonde en position centrale et un ou plusieurs détecteurs déplaçables en positions circonférentielles
69.
Crystal of cytidine diphosphate choline and production method thereof
An object of the present invention is to provide a crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties, and a production method thereof. According to the present invention, the crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties can be obtained by precipitating the crystal of cytidine diphosphate choline in an aqueous solution in which cytidine diphosphate choline is dissolved, collecting the precipitated crystal of cytidine diphosphate choline, and washing the collected crystal of cytidine diphosphate choline with an aqueous solution containing an organic solvent other than methanol in which a water content is 5% to 50% by volume.
An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
C07C 277/06 - Purification ou séparation de guanidine
C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
71.
Crystal of 3'-sialyllactose sodium salt n-hydrate, and process for producing same
An object of the present invention is to provide a crystal of 3′-sialyllactose (hereinafter, referred to as 3SL), which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a process for producing the same. The present invention relates to a 3SL sodium salt n-hydrate (wherein n represents any number of 0 to 9, and when n is 0, it is referred to as 3SL sodium salt anhydrate) and a process for producing the same.
The present invention provides a crystal of reduced glutathione having excellent powder properties and a method for producing the same. The present invention relates to a crystal of reduced glutathione, wherein the average crystal thickness is 10 μm or more.
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C30B 7/08 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par refroidissement de la solution
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
73.
Crystal of reduced glutathione and method for producing same
According to the present invention, a crystal of reduced glutathione having a reduced content of impurities, particularly L-cysteinyl-L-glycine and a method for producing the same are provided. The present invention relates to a crystal of reduced glutathione, wherein, in a high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to the peak area of reduced glutathione which is taken as 100.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C30B 7/14 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses le matériau à cristalliser étant produit dans la solution par des réactions chimiques
C30B 33/00 - Post-traitement des monocristaux ou des matériaux polycristallins homogènes de structure déterminée
C30B 7/08 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par refroidissement de la solution
C30B 7/10 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par application d'une pression, p. ex. procédés hydrothermiques
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
The invention provides citrulline or a salt thereof and glutathione or a salt thereof for use in increasing a ratio of muscle mass to total body weight in a person in conjunction with a resistance workout program, as well as a method of increasing a ratio of muscle mass to total body weight in a person by administering citrulline or a salt thereof and glutathione or a salt thereof to the person in conjunction with a resistance workout program. The citrulline and glutathione or salts thereof are administered daily for a period greater than 7 days, whereas the resistance workout program is administered for at least the entire period during which the two compounds are administered. The muscle mass is measured by a body composition meter.
The present invention provides a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (hereinafter, referred to as HMB), which is excellent in solubility and easy to handle, and a process for producing the crystal. A crystal of a monovalent cation salt of HMB is precipitated in an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 9.0, and the crystal of a monovalent cation salt of HMB is thereafter collected from the aqueous solution.
C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
C30B 7/10 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par application d'une pression, p. ex. procédés hydrothermiques
An object of the present invention is to provide a crystal of 6′-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
C07H 13/04 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés à des atomes de carbone acycliques
C07H 1/00 - Procédés de préparation des dérivés du sucre
According to the present invention, it becomes possible to produce theanine with high efficiency without requiring adding ethylamine from the outside and without accumulating or remaining ethylamine as a by-product, by using a microorganism which has an enhanced activity to produce ethylamine using acetaldehyde and alanine as substrates and an enhanced γ-glutamylmethylamide synthase activity or an enhanced glutaminase activity.
The present invention provides a medium for inducing the differentiation of stem cells into mesodermal cells, the medium including a ROCK inhibitor, a bone morphogenetic protein (BMP), a fibroblast growth factor (FGF), and activin. The present invention also provides a method for producing mesodermal cells from stem cells using the medium, and a method for producing cardiac progenitor cells or myocardiocytes from stem cells using the medium. The present invention furthermore provides a composition for assisting the induction of differentiation of stem cells into mesodermal cells, the composition including a ROCK inhibitor, a BMP, an FGF, and activin. The present invention additionally provides cell groups obtained by the above methods.
The present invention relates to a crystals of glutathione trisulfide dihydrate and a method for producing the same. According to the present invention, for example, by concentrating a solution in which glutathione trisulfide is dissolved and then harvesting crystals of the precipitated glutathione trisulfide dihydrate, such crystals can be provided. The present invention also relates to a simple method for producing polysulfide in an aqueous solvent where hydrogen sulfide is not used but thiosulfate is used, the polysulfide being produced by agitating or leaving to stand a solution in which a compound having a thiol group or a disulfide bond and a thiosulfate are dissolved.
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
The purpose of the present invention is to provide L-alanyl-L-glutamine crystals having a low rough specific volume, and a method for producing same. This invention pertains to L-alanyl-L-glutamine crystals having a rough specific ratio not exceeding 5.0 mL/g, and a method for producing same.
C07C 237/04 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
G01N 23/207 - Diffractométrie, p. ex. en utilisant une sonde en position centrale et un ou plusieurs détecteurs déplaçables en positions circonférentielles
84.
Method for producing alpha-form crystal of reduced glutathione, and method for storing said crystal
The invention provides a method of efficiently and stably producing α-form crystal of reduced glutathione, and a preservation method thereof. According to the invention, development of β-form crystal and/or transition to β-form crystal of reduced glutathione are suppressed by the coexistence of at least one kind of compound selected from the group of aliphatic amino acid, sulfur-containing amino acid, aromatic amino acid, an analogous compound and dipeptide, as a habit modifier, during production and preservation of an aqueous solution or α-form crystal of reduced glutathione.
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
C07K 1/02 - Procédés généraux de préparation de peptides en solution
C07K 1/30 - ExtractionSéparationPurification par précipitation
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
The purpose of the present invention is to provide: crystals of cytidine diphosphate choline which contain no methanol and have improved powder properties; and a process for producing the crystals. The process according to the present invention comprises precipitating crystals of cytidine diphosphate choline in an aqueous solution containing cytidine diphosphate choline dissolved therein, collecting the precipitated crystals of cytidine diphosphate choline, and washing the collected crystals of cytidine diphosphate choline with an aqueous solution of an organic solvent other than methanol, the aqueous solution having a water content of 5-50 vol%. Thus, crystals of cytidine diphosphate choline which contain no methanol and have improved powder properties can be obtained.
The present invention provides a crystal of reduced glutathione that is stable, and is easy to process, and a method for producing the crystal. According to the present invention, a crystal of a metal salt of reduced glutathione is produced by suspending an amorphous solid of a metal salt of reduced glutathione in a hydrophobic organic solvent, and adding water to the resulting suspension to precipitate a crystal of a metal salt of reduced glutathione.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements including citrulline and arginine; Dietary supplements; Dietetic foods adapted for medical purposes; Dietetic beverages adapted for medical purposes; Amino acids for medical purposes; Amino acids for nutritional purpose; Food supplements consisting of amino acids; Arginine, namely, an amino acid for nutritional purposes; Citrulline, namely, an amino acid for nutritional purposes.
88.
CRYSTALS OF β-NICOTINAMIDE MONONUCLEOTIDE AND PRODUCTION PROCESS THEREFOR
The purpose of the present invention is to provide: crystals of β-nicotinamide mononucleotide (NMN) which have excellent storage stability; and a production process therefor. According to the present invention, crystals of NMN can be precipitated from an alcohol solution containing NMN dissolved therein, by allowing the solution to stand still or stirring the solution. Crystals of NMN can be precipitated from an aqueous solution containing NMN dissolved therein, by dissolving an alcohol solution in the aqueous solution.
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
89.
MEDIUM FOR CULTURING STEM CELLS, METHOD FOR CULTURING STEM CELLS, STEM CELL GROWTH PROMOTER, AND CELL COMPOSITION AND METHOD FOR PRODUCING SAME
The purpose of the present invention is to provide a technique for stably, economically and safely culturing stem cells having differentiation ability while maintaining the cells in the undifferentiated state. The present invention pertains to: a medium for culturing stem cells, said medium containing at least one compound selected from the group consisting of a ROCK inhibitor, a PKC inhibitor, a histone methyltransferase inhibitor and a retinoic acid receptor agonist and being free from growth factors or having a low growth factor concentration; a method for culturing stem cells with the use of the medium; a stem cell growth promoter; a cell composition comprising stem cells or cells differentiated therefrom; and a method for producing the cell composition.
The invention provides a double-stranded ribonucleic acid (dsRNA) having a chain length suitable for simultaneously showing low toxicity and high function in the use of an adjuvant and the like, and resisting variation of chain length even when subjected to a heating and cooling treatment, or a salt thereof; an immune potentiator, adjuvant, pharmaceutical product and the like containing the dsRNA and the like; and a production method of such dsRNA and the like. The invention is characterized in that the weight average chain length of two or more single-stranded ribonucleic acids (ssRNAs) constituting the first chain constituting dsRNA is not more than ½ of the weight average chain length of one ssRNA constituting the second chain.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p. ex. contenant des motifs CpG
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
91.
Crystal of ammonium N-acetylneuraminate anhydrate, and process for producing same
According to the present invention, a crystal of ammonium N-acetylneuraminate anhydrate, and a process for producing a crystal of ammonium N-acetylneuraminate anhydrate, comprising adding or adding dropwise a solvent selected from the group consisting of alcohols and ketones to an aqueous N-acetylneuraminic acid solution containing an ammonium-containing compound and having a pH of 3.0 to 9.0 to precipitate a crystal of ammonium N-acetylneuraminate anhydrate, and collecting the crystal of ammonium N-acetylneuraminate anhydrate from the aqueous solution, can be provided.
The purpose of the present invention is to provide: a crystal of HMB amino acid salt, which is easy to handle and is highly soluble; and a production method of said crystal. According to the present invention, a crystal of HMB amino acid salt can be precipitated by dissolving HMB amino acid salt in an amorphous state in a solvent containing an alcohol and by agitating said solvent or leaving said solvent still. In addition, a crystal of HMB amino acid salt can be precipitated by concentrating an HMB amino acid salt aqueous solution having a pH of 2.5-11.0.
C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 51/43 - SéparationPurificationStabilisationEmploi d'additifs par changement de l'état physique, p. ex. par cristallisation
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
93.
CRYSTAL OF 3'-SIALYLLACTOSE SODIUM SALT N-HYDRATE, AND METHOD FOR PRODUCING SAME
The present invention addresses the problem of providing: a crystal of 3'-sialyllactose (also referred to as "3SL", hereinafter), which is easy to handle and has high storage stability under ambient-temperature and high-temperature conditions; and a method for producing the crystal. The present invention relates to: a crystal of a 3SL sodium salt n-hydrate (wherein n represents an arbitrary numerical value of 0 to 9, and the 3SL sodium salt n-hydrate refers to as "3SL sodium salt anhydride" when n is 0); and a method for producing the crystal.
The purpose of the invention is to provide an albumin-free medium for serum-free culture of pluripotent stem cells capable of maintaining the undifferentiation and pluripotency (pluripotential) of pluripotent stem cells, an additive for albumin-free medium, and a culture method. The albumin-free medium for serum-free culture of pluripotent stem cells, additive for albumin-free medium, and medium used in the culture method of the present invention are characterized by containing at least one selected from the group consisting of Pluronic nonionic surfactants, animal-based hydrolysates, and nonanimal-based hydrolysates.
The present application provides a naïve pluripotential stem cell culturing medium for efficiently proliferating naïve pluripotent stem cells while maintaining the non-differentiation and pluripotency (multipotency) thereof. The medium of the present application contains a ROCK inhibitor at a concentration of 5 μM or less.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
96.
CRYSTAL OF REDUCED-FORM GLUTATHIONE AND METHOD FOR PRODUCING SAME
The invention provides a crystal of glutathione having excellent flowability and pulverizability, and a method for producing the same. The invention relates to a crystal of reduced-form glutathione, wherein the average crystal thickness is 10 µm or greater.
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C30B 7/08 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par refroidissement de la solution
The purpose of the invention is to provide: a crystal of reduced-form glutathione in which the content of impurities, particularly L-cysteinyl-L-glycine, is reduced; and a method for producing the same. The invention relates to a crystal of reduced-form glutathione wherein, in high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to a peak area of 100 of the reduced-form glutathione.
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
According to the present invention, a crystal of an alkali metal N-acetylneuraminate anhydrate, and a process for producing a crystal of an alkali metal N-acetylneuraminate anhydrate, comprising adding or adding dropwise a solvent selected from the group consisting of alcohols and ketones to an aqueous N-acetylneuraminic acid solution containing an alkali metal-containing compound and having a pH of 3.0 to 9.0 to precipitate a crystal of an alkali metal N-acetylneuraminate anhydrate, and collecting the crystal of an alkali metal N-acetylneuraminate anhydrate from the aqueous solution, can be provided.
Labyrinthulea microorganism in which sterol 24-C-methyltransferase activity is reduced or lost as compared to a parent strain, allowing 7DHC to be produced and accumulated in the culture, and collecting the 7DHC from the culture; and a process for producing vitamin D3, comprising irradiating, with ultraviolet light, 7-dehydrocholesterol produced by the production process.
C07C 401/00 - Produits d'irradiation du cholestérol ou de ses dérivésDérivés de vitamine D, séco-9,10 cyclopenta[a]phénanthrène ou leurs analogues obtenus par préparation chimique sans irradiation
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.
